| 4.22 0.005 (0.12%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.4 | 1-year : | 6.09 |
| Resists | First : | 4.62 | Second : | 5.21 |
| Pivot price | 4.13  |
|||
| Supports | First : | 3.67 | Second : | 3.05 |
| MAs | MA(5) : | 4.3 |
MA(20) : | 4.18 |
| MA(100) : | 3.65 |
MA(250) : | 4.23 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 31 |
D(3) : | 43.2 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 5.86 | Low : | 2.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GNTA ] has closed below upper band by 38.7%. Bollinger Bands are 15.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.61 - 4.63 | 4.63 - 4.65 |
| Low: | 4.07 - 4.09 | 4.09 - 4.11 |
| Close: | 4.18 - 4.22 | 4.22 - 4.25 |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Mon, 02 Sep 2024
Genenta Science S.p.A. (NASDAQ:GNTA) Sees Significant Decrease in Short Interest - MarketBeat
Tue, 17 Jan 2023
Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer - Business Wire
Tue, 04 Oct 2022
ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 18 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 38.8 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | -0.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.3 % |
| Return on Equity (ttm) | -45.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -5.95 |
| PEG Ratio | 0 |
| Price to Book value | 3.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|